Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03119610
Other study ID # HSC20160661H
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date September 22, 2017
Est. completion date December 17, 2019

Study information

Verified date September 2020
Source The University of Texas Health Science Center at San Antonio
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Obesity is highly prevalent in older adults and is a major cause of sarcopenia and disability in older adults. Although exercise can counteract the effects of obesity and sarcopenia, many have difficulty adhering to an exercise program and the benefits of exercise are variable. Therefore, there is an urgent need to test novel pharmacologic interventions to prevent disability and loss of independence. Oxytocin is a pituitary hormone released during parturition and lactation that is also known to suppress appetite in rodents and humans; and, recent small studies have found that intranasal oxytocin reduces body weight in adults. We propose a pilot study of intranasal oxytocin as a novel approach to promote weight loss and increase muscle mass in older subjects with sarcopenic obesity.


Description:

The pilot study will be conducted at 3 sites in 9 visits over a period of 12+ weeks. Older sedentary subjects will be screened for sarcopenic obesity using a modified consensus definition and evaluated at baseline for safety labs, glucose tolerance, body composition, cognition and physical performance, as well as systemic inflammatory markers in blood and muscle tissue. Eligible subjects self-administer 24 IU intranasal oxytocin four times a day for 8 weeks. The study will examine whether the intervention will promote weight loss and preserve muscle mass, thereby preserving and/or improving physical function in older subjects with sarcopenic obesity. Generalized linear mixed effects model will be used to evaluate the effect of oxytocin on the change of each continuous measure. The effect of oxytocin will be assessed by whether the time by oxytocin interaction is significantly different from 0 with a 2-sided p-value<0.05.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date December 17, 2019
Est. primary completion date December 17, 2018
Accepts healthy volunteers No
Gender All
Age group 60 Years to 99 Years
Eligibility Inclusion Criteria: - BMI 30-40 kg/m2 - Sedentary (< 2 strenuous exercise/week) - Gait speed < 1 meter/second Exclusion Criteria: - Diabetes (ADA criteria) - Heart disease (MI or New York Heart Classification grade III-IV) - Poorly controlled hypertension (SBP > 170 or DBP >95 mm/Hg) - Anemia (Hematocrit <34%) - Renal Disease (Serum Creatinine >1.4, abnormal serum sodium levels, abnormal urinalysis, or physical exam findings indicative of fluid imbalance; individuals with underlying disorder of sodium/water balance, such as SIADH, diabetes insipidus, or psychogenic polydipsia) - Liver Disease (AST/ALT/AlkPhos > 2x upper limit of normal) - Use of systemic steroid, androgens, or anti-coagulants - Active/unstable conditions: inflammatory, thyroid, autoimmune, gastrointestinal (GI), hematologic, or neoplastic disorders - Individuals with underlying seizure disorder or underlying neurologic disorder that increases seizure risk - Cognitive impairment (MiniCog <3), unstable mental illness, substance abuse, or history of eating disorder

Study Design


Intervention

Drug:
Oxytocin nasal spray
Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)
Placebo nasal spray
Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)

Locations

Country Name City State
United States Texas Diabetic Institute San Antonio Texas

Sponsors (4)

Lead Sponsor Collaborator
Sara Espinoza The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center, Houston, The University of Texas Medical Branch, Galveston

Country where clinical trial is conducted

United States, 

References & Publications (1)

Espinoza SE, Lee JL, Wang CP, Ganapathy V, MacCarthy D, Pascucci C, Musi N, Volpi E. Intranasal Oxytocin Improves Lean Muscle Mass and Lowers LDL Cholesterol in Older Adults with Sarcopenic Obesity: A Pilot Randomized Controlled Trial. J Am Med Dir Assoc. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Body Weight Intranasal oxytocin will promote weight loss and preserve muscle mass Baseline to 8 weeks
Secondary Change in Fat Mass Pre- and post-measurements of fat mass by dual energy x-ray absorptiometry (DXA) will be examined for individual change with intranasal oxytocin Baseline to 8 weeks
Secondary Change in Body Mass Index Pre- and post-measurements of lean mass by DXA will be examined for individual change with intranasal oxytocin. Change in body mass index (BMI). 8 weeks
Secondary Change in Glucose Levels Measured Using the Glucose Tolerance Test Pre- and post-measurements of oral glucose tolerance test for 2-hour plasma glucose will be examined for individual change with intranasal oxytocin 8 weeks
Secondary Change in Short Physical Performance Battery (SPPB) Pre- and post-measurements will be examined for individual change with intranasal oxytocin. This battery of tests is scored on a scale with 3 SPPB calculation components:
Ability to stand for 10 seconds with feet in 3 different positions, scored from 0 min to 4 maximum, with a higher score indicating better balance.(3 Balance subsets: side by side stand scored from 0-1; semi-tandem stance scored from 0-1; tandem stance scored from 0-2)
Two timed trials of a 3m or 4 m walk (fastest recorded). Scoring is from 0-4, with 0 being unable to walk and 4 indicating a faster walk time.
Time to rise from a chair five times is scored from 0-4, with 0 being unable to complete the activity, and 4 indicating that time to complete is less than 11.1 seconds.
Total Score is the sum of all 3 scores: Minimum = 0 Maximum = 12. Higher scores indicate better lower extremity function.
Difference between baseline and 8 week performance is reported.
Baseline to 8 weeks
Secondary Change in HbA1c (Hemoglobin A1c) Pre- and post-measurements will be examined for individual change with intranasal oxytocin Baseline to 8 weeks
Secondary Change in Waist Circumference Pre- and post-measurements will be examined for individual change with intranasal oxytocin Baseline to 8 weeks
Secondary Change in Total Cholesterol Pre- and post-measurements will be examined for individual change with intranasal oxytocin Baseline to 8 weeks
Secondary Change in Low Density Lipoproteins (LDL) Pre- and post-measurements will be examined for individual change with intranasal oxytocin Baseline to 8 weeks
Secondary Change in High Density Lipoproteins (HDL) Pre- and post-measurements will be examined for individual change with intranasal oxytocin Baseline to 8 weeks
Secondary Change in Triglycerides Pre- and post-measurements will be examined for individual change with intranasal oxytocin Baseline to 8 weeks
Secondary Change in Center for Epidemiologic Studies Scale (CES-D) Pre- and post-measurements will be examined for individual change with intranasal oxytocin. This is measured on a 20 item scale using the following scoring using number of week days:
Rarely or none of the time ( less than 1 day)
Some or a little of the time (1-2 days)
Occasionally or a moderate amount of time (3-4 days)
Most or all of the time (5-7 days) SCORING: zero for answers =1), 1 for answers =2), 2 for answers =3) column, 3 for answers =4) The scoring of positive items is reversed. Possible range of scores is zero to 60, with the higher scores indicating the presence of more symptomatology.
Baseline to 8 weeks
Secondary Change in Montreal Cognitive Assessment (MoCA) Pre- and post-measurements will be examined for individual change with intranasal oxytocin. A 30-point test, with a score of 0 or 1 assigned to each item. The minimum score is 0 and the maximum is 30. The higher the score, the less cognitive impairment. Baseline to 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2